Zai Lab (ZLAB) said Tuesday that a phase 3 trial evaluating the safety and efficacy of KarXT in patients with schizophrenia in China met its primary endpoint as it demonstrated a statistically significant reduction in Positive and Negative Syndrome Scale total score compared with placebo at week 5.
The trial, which enrolled 202 acutely psychotic hospitalized adults in China, also met all key secondary efficacy endpoints, according to the company.
The results are from the 5-week double-blind segment of the study that will be followed by a 12-week open-label extension, Zai Lab added.
The biopharmaceutical company said it is planning to submit a new drug application for approval in China in early 2025.
Shares of the company were down 2.8% in recent trading.
Price: 31.64, Change: -0.90, Percent Change: -2.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。